NEW YORK, March 23 – Vincent Kazmer said Friday he was resigning as chief financial officer of NetGenics to join Phase-1 Molecular Toxicology as CEO.

“Phase-1 is a good opportunity,” Kazmer said. His resignation is effective immediately and he will start work at Phase-1 Molecular Toxicology in April.

The company, which is based in Santa Fe, NM, uses gene expression technologies and bioinformatics to help improve lead optimization and diminish toxic effects early in a drug’s development.

Phase-1’s founder Spencer Farr will head the company’s R&D division.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.